Twist Bioscience Co. (NASDAQ:TWST) Insider Dennis Cho Sells 276 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWSTGet Free Report) insider Dennis Cho sold 276 shares of the firm’s stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $51.33, for a total transaction of $14,167.08. Following the completion of the sale, the insider now directly owns 80,160 shares of the company’s stock, valued at approximately $4,114,612.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Dennis Cho also recently made the following trade(s):

  • On Wednesday, March 20th, Dennis Cho sold 230 shares of Twist Bioscience stock. The stock was sold at an average price of $33.52, for a total transaction of $7,709.60.
  • On Thursday, March 14th, Dennis Cho sold 93 shares of Twist Bioscience stock. The stock was sold at an average price of $34.60, for a total transaction of $3,217.80.

Twist Bioscience Stock Down 0.9 %

TWST opened at $50.01 on Tuesday. Twist Bioscience Co. has a 12 month low of $14.42 and a 12 month high of $54.13. The firm’s fifty day simple moving average is $38.32 and its 200 day simple moving average is $35.86.

Twist Bioscience (NASDAQ:TWSTGet Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.05. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. The firm had revenue of $75.30 million for the quarter, compared to analysts’ expectations of $70.70 million. During the same period in the previous year, the firm posted ($1.06) EPS. The company’s revenue for the quarter was up 25.1% on a year-over-year basis. On average, research analysts predict that Twist Bioscience Co. will post -3.08 earnings per share for the current year.

Institutional Investors Weigh In On Twist Bioscience

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. UBS Group AG raised its holdings in shares of Twist Bioscience by 106.4% in the 4th quarter. UBS Group AG now owns 213,467 shares of the company’s stock valued at $7,868,000 after purchasing an additional 110,036 shares during the period. Nikko Asset Management Americas Inc. increased its holdings in shares of Twist Bioscience by 2.9% during the fourth quarter. Nikko Asset Management Americas Inc. now owns 3,583,443 shares of the company’s stock worth $131,835,000 after purchasing an additional 99,511 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of Twist Bioscience by 3.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 442,504 shares of the company’s stock worth $8,965,000 after purchasing an additional 14,511 shares during the period. Artisan Partners Limited Partnership increased its holdings in shares of Twist Bioscience by 111.3% during the fourth quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company’s stock worth $137,241,000 after purchasing an additional 1,961,621 shares during the period. Finally, State Board of Administration of Florida Retirement System increased its holdings in shares of Twist Bioscience by 559.5% during the third quarter. State Board of Administration of Florida Retirement System now owns 106,572 shares of the company’s stock worth $2,159,000 after purchasing an additional 90,413 shares during the period.

Analyst Ratings Changes

TWST has been the subject of a number of analyst reports. Robert W. Baird lifted their target price on shares of Twist Bioscience from $39.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd. Guggenheim initiated coverage on shares of Twist Bioscience in a report on Tuesday, June 4th. They set a “buy” rating and a $53.00 target price for the company. Barclays boosted their price target on shares of Twist Bioscience from $40.00 to $45.00 and gave the company an “overweight” rating in a report on Friday, May 3rd. Evercore ISI boosted their price target on shares of Twist Bioscience from $46.00 to $50.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. Finally, Scotiabank boosted their price target on shares of Twist Bioscience from $43.00 to $48.00 and gave the company a “sector outperform” rating in a report on Monday, May 6th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $44.00.

View Our Latest Stock Report on Twist Bioscience

About Twist Bioscience

(Get Free Report)

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

Featured Stories

Insider Buying and Selling by Quarter for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.